RANVET'S PERGOLIDE

Nazione: Australia

Lingua: inglese

Fonte: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Principio attivo:

PERGOLIDE MESYLATE

Commercializzato da:

RANVET PTY. LIMITED

INN (Nome Internazionale):

pergolide mesylate(1mg/5mL)

Forma farmaceutica:

ORAL SOLUTION/SUSPENSION

Composizione:

PERGOLIDE MESYLATE AMINO Active 1.0 mg/5ml

Confezione:

200mL

Classe:

VM - Veterinary Medicine

Gruppo terapeutico:

HORSE | PONY | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT STUD | MARE | PACE

Area terapeutica:

ENDOCRINE SYSTEM

Indicazioni terapeutiche:

CUSHINGS DISEASE | HYPERADRENOCORTISISM | PITUITARY DEPENDENT HYPERDRENO

Dettagli prodotto:

Poison schedule: 4; Withholding period: MEAT WHP (HORSES): NOT TO BE USED in h orse intended for human consumption.; Host/pest details: HORSE: [CUSHINGS DISEASE]; PONY: [CUSHINGS DISEASE]; Poison schedule: 4; Withholding period: ; Host/pest details: HORSE: [CUSHINGS DISEASE]; PONY: [CUSHINGS DISEASE]; Aids in the therapy of equine Cushing's syndrome.This product is contraindicated in horses hypersensitive to it or other ergot derivatives. Use with caution in pregnant or lactating mares as safe use in these groups has not been established.

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2022-07-01

Foglio illustrativo

R
T PT
LTD
ANVE
ty
Ranvet's Pergolide -
Main Panel
Date:
September
13,
2010
Version:
3
Page 1
of
1
CIN
:
000
Carton Label
Anything
above
this
line
is
not
draft
/
text
label.
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
RANVET'S PERGOLIDE
Active
Constituent:
Pergalide mesylate 1mg/5mL
Aids in the therapy of equine Cushing's syndrome
200
mL RLP APPROVED
Info
PEST


Verified
RANVET PTY LTD
Ranvet's
Pergolide
-
Ancillary
Panels
Date:
September
13,
2010
Version:
3
Page 2
of
1
CIN
:
000
Carton Label
Anything
above
this
line is
not
draft
/
text
label.
INDICATlONS
Pergolide mesylate is a potent dopamine agonist
for the control
of clinical
signs
associated with equine Cushing's syndrome in horses and ponies.
These signs
may include lethargy ; long, poor-quality hair coat that
fails to shed; weight
loss;
pot-bellied appearance ; dry scaly skin;
skin infections;
polyuria (increased
frequency of urination) and polydipsia (increased drinking) ; chronic
laminitis and
colic .
DIRECTIONS FOR USE
Contraindications:
This product
is contraindicated in horses hypersensitive to it or other ergot
derivatives.
Precautions:
Use with caution in pregnant
or lactating mares as safe use in these groups has not
been established.
Dosage and
administration:
Administer orally over the tongue once daily. A syringe should be used
for accurate
dose measurement.
An initial
starting dose of 0.002mg/kg
(1
mg/500kg bodyweight)
daily is
recommended.
Each 5mLdose provides 1mg pergolide mesylate.
The dose may be
gradually increased if clinical
improvement fails to occur after one to two months of
therapy.
Consult
your veterinarian before altering the recommended dose.
If the
dose is to be increased it is recommended that
0.5mg increments be assessed
before higher daily doses are employed.
A favourable clinical
response to therapy will
be associated with improvement or
normalisation of results in the dexamethasone suppression and plasma
ACTH tests
and an improvement in clinical
signs .
Treatment will
be required for t